Trials / Unknown
UnknownNCT05802108
Effect of PCSK9 Inhibitor on Retinal Microvessels in Patients With Coronary Heart Disease After Intensive Lipid-lowering Therapy
- Status
- Unknown
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- Zibo Central Hospital · Other Government
- Sex
- All
- Age
- 50 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
In patients with coronary heart disease who were treated with PCSK9 inhibitor evolocumab for intensive lipid-lowering therapy, the changes of retinal microvessels were measured with OCTA (Optical Coherence Tomography Angiography)before and after the treatment. The specific indicators included retinal microvessel diameter, macular area，optic disc vascular density and FAZ(Foveal Avascular Zone)area, etc., to clarify the effect of evolocumab on retinal microvessels after intensive lipid-lowering therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Evolocumab combined with statins | The experimental group was treated with evolocumab combined with statin for lipid-lowering |
| DRUG | Statin | the control group was treated with statin only for lipid-lowering |
Timeline
- Start date
- 2022-07-01
- Primary completion
- 2024-06-30
- Completion
- 2024-06-30
- First posted
- 2023-04-06
- Last updated
- 2023-04-06
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05802108. Inclusion in this directory is not an endorsement.